Praxis Precision Medicines Inc (PRAX) Stock Analysis
Verdict: AVOID
POWER1 trial primary endpoint miss invalidates the current valuation floor, shifting all risk to high-dose efficacy results due in 2027.
Investment score: 38/100
Analysis as of
Is Praxis Precision Medicines Inc stock worth reviewing? AI model thesis
Avoid until the clinical path for vormalatrigine is de-risked and the burn rate is addressed.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Praxis Precision Medicines Inc opportunities and risks
What speaks for PRAX
- High-Dose vormalatrigine Efficacy
What speaks against PRAX
- Dilutive Equity Financing Primary risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.2% |
| HALO | 22.4x | 5.2x | 10.1x | 76.9% | 23.1% | 8.5% |
| IBRX | n/a | 53.7x | n/a | 93.8% | -606.2% | -3.9% |
| NUVL | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.7% |
| PCVX | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.3% |
| LEGN | n/a | 5.9x | n/a | 55.0% | -22.0% | -3.5% |
| Peer median | n/a | 5.2x | n/a | 55.0% | 0.0% | -3.9% |
Frequently asked questions about Praxis Precision Medicines Inc (PRAX)
Is PRAX stock a good investment?
The cached TradeMates AI model rates Praxis Precision Medicines Inc as AVOID with an investment score of 38/100. Avoid until the clinical path for vormalatrigine is de-risked and the burn rate is addressed. This is algorithmic model output, not personal investment advice.
Is PRAX stock a buy?
The TradeMates model verdict for PRAX is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.